Rethinking the delivery of biologics in the treatment of cancer

References:

1. O’Shaughnessy J, et al. Eur J Cancer 2021;152:223-232;
2. Bittner B, et al. BioDrugs 2018;32:425–440;
3. Leveque D. Anticancer Res 2014;34:1579–86;
4. Anderson KC, et al. Future Oncol 2019;15:3267–3281;
5. Stoner KL, et al. Patient 2014;8:45–153;
6. McCloskey C, et al. Pharmacoecon Open 2023;7:3–36;
7. De Cock E, et al. Value Health 2014;17:A653;
8. Davies A, et al. Lancet Oncol 2014;15:343–52;
9. Ismael G, et al. Lancet Oncol 2012;13:869–78;
10. Usmani SZ, et al. Blood 2016;128:1149;
11. Badkar AV, et al. Drug Des Devel Ther 2021;15:159–170.